Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Dec;59(12):4555–4561. doi: 10.1128/iai.59.12.4555-4561.1991

Relation between structure and immunologic properties of the Vi capsular polysaccharide.

S C Szu 1, X R Li 1, A L Stone 1, J B Robbins 1
PMCID: PMC259077  PMID: 1937814

Abstract

The Vi capsular polysaccharide of Salmonella typhi is a linear homopolymer of poly-alpha(1----4)GalNAcp variably O acetylated at the C-3 position. Serum antibodies elicited by this antigen confer protective immunity against typhoid fever. The relation between the immunologic properties and structure of Vi was investigated by carboxyl reduction, O deacetylation, and acid hydrolysis. The immunogenicity of Vi was closely related to its degree of O acetylation. Partial O deacetylation slightly increased immunogenicity; complete O deacetylation eliminated the immunogenicity of Vi. O-deacetylated Vi, however, still reacted with antisera prepared by injection of whole bacteria. Carboxyl reduction, in contrast, had a comparatively slight effect upon both the immunogenicity and antigenicity of Vi. Retention levels of antigenicity after acid treatment were greater for both the native and carboxyl-reduced Vi than for the O-deacetylated product. The Courtauld-Koltun space-filling model of a pentamer of Vi demonstrated that the bulky nonpolar O-acetyls, which protrude in rows on both sides, make up most of the surface. The carboxyls are less exposed and are partially shielded by the O-acetyls. The molecular model thus provides an explantation for the dominant role of the O-acetyls, as well as the lesser effect of carboxyl reduction, upon the immunologic properties of Vi.

Full text

PDF
4555

Images in this article

4556Image
on p.4556
4557Image
on p.4557
4559Image
on p.4559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acharya I. L., Lowe C. U., Thapa R., Gurubacharya V. L., Shrestha M. B., Cadoz M., Schulz D., Armand J., Bryla D. A., Trollfors B. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101–1104. doi: 10.1056/NEJM198710293171801. [DOI] [PubMed] [Google Scholar]
  2. Apicella M. A. Identification of a subgroup antigen on the Neisseria meningitidis group C capsular polysaccharide. J Infect Dis. 1974 Feb;129(2):147–153. doi: 10.1093/infdis/129.2.147. [DOI] [PubMed] [Google Scholar]
  3. Bax A., Summers M. F., Egan W., Guirgis N., Schneerson R., Robbins J. B., Orskov F., Orskov I., Vann W. F. Structural studies of the Escherichia coli K93 and K53 capsular polysaccharides. Carbohydr Res. 1988 Feb 15;173(1):53–64. doi: 10.1016/s0008-6215(00)90802-4. [DOI] [PubMed] [Google Scholar]
  4. Bhattacharjee A. K., Jennings H. J., Kenny C. P., Martin A., Smith I. C. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem. 1975 Mar 10;250(5):1926–1932. [PubMed] [Google Scholar]
  5. Guirguis N., Schneerson R., Bax A., Egan W., Robbins J. B., Shiloach J., Orskov I., Orskov F., el Kholy A. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med. 1985 Dec 1;162(6):1837–1851. doi: 10.1084/jem.162.6.1837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hornick R. B., Woodward T. E. Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc. 1967;78:70–78. [PMC free article] [PubMed] [Google Scholar]
  7. Jennings H. J., Lugowski C., Kasper D. L. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry. 1981 Aug 4;20(16):4511–4518. doi: 10.1021/bi00519a001. [DOI] [PubMed] [Google Scholar]
  8. KABAT E. A., BEZER A. E. The effect of variation in molecular weight on the antigenicity of dextran in man. Arch Biochem Biophys. 1958 Dec;78(2):306–318. doi: 10.1016/0003-9861(58)90354-0. [DOI] [PubMed] [Google Scholar]
  9. Kabat E. A., Liao J., Osserman E. F., Gamian A., Michon F., Jennings H. J. The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV. J Exp Med. 1988 Aug 1;168(2):699–711. doi: 10.1084/jem.168.2.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kabat E. A., Nickerson K. G., Liao J., Grossbard L., Osserman E. F., Glickman E., Chess L., Robbins J. B., Schneerson R., Yang Y. H. A human monoclonal macroglobulin with specificity for alpha(2----8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. J Exp Med. 1986 Aug 1;164(2):642–654. doi: 10.1084/jem.164.2.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelly T. E., Taylor H. A. Leucocyte values of alpha-L-iduronidase activity in mucopolysaccharidosis I. J Med Genet. 1976 Apr;13(2):149–151. doi: 10.1136/jmg.13.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klugman K. P., Gilbertson I. T., Koornhof H. J., Robbins J. B., Schneerson R., Schulz D., Cadoz M., Armand J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov 21;2(8569):1165–1169. doi: 10.1016/s0140-6736(87)91316-x. [DOI] [PubMed] [Google Scholar]
  13. LANDY M. Studies on Vi antigen. VII. Characteristics of the immune response in the mouse. Am J Hyg. 1957 Jan;65(1):81–93. doi: 10.1093/oxfordjournals.aje.a119858. [DOI] [PubMed] [Google Scholar]
  14. Lee C. J., Pearson S. J., Robbins J. B. Quantitative determination of pneumococcal capsular polysaccharides in the polyvalent vaccine. I. Standardization of an immunoelectrophoretic method. J Biol Stand. 1980;8(4):271–280. doi: 10.1016/s0092-1157(80)80004-7. [DOI] [PubMed] [Google Scholar]
  15. Martin D. G., Jarvis F. G., Milner K. C. Physicochemical and biological properties of sonically treated Vi antigen. J Bacteriol. 1967 Nov;94(5):1411–1416. doi: 10.1128/jb.94.5.1411-1416.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nolan C. M., LaBorde E. A., Howell R. T., Robbins J. B. Identification of Salmonella typhi in faecal specimens by an antiserum-agar method. J Med Microbiol. 1980 May;13(2):373–377. doi: 10.1099/00222615-13-2-373. [DOI] [PubMed] [Google Scholar]
  17. Orskov F., Orskov I., Sutton A., Schneerson R., Lin W., Egan W., Hoff G. E., Robbins J. B. Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med. 1979 Mar 1;149(3):669–685. doi: 10.1084/jem.149.3.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Robbins J. D., Robbins J. B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis. 1984 Sep;150(3):436–449. doi: 10.1093/infdis/150.3.436. [DOI] [PubMed] [Google Scholar]
  19. Stone A. L., Szu S. C. Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever. J Clin Microbiol. 1988 Apr;26(4):719–725. doi: 10.1128/jcm.26.4.719-725.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Szewczyk B., Taylor A. Immunochemical properties of Vi antigen from Salmonella typhi Ty2: presence of two antigenic determinants. Infect Immun. 1980 Aug;29(2):539–544. doi: 10.1128/iai.29.2.539-544.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Szu S. C., Li X. R., Schneerson R., Vickers J. H., Bryla D., Robbins J. B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun. 1989 Dec;57(12):3823–3827. doi: 10.1128/iai.57.12.3823-3827.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Szu S. C., Oravec L. S. Detection of "neutral" type 7F and type 14 pneumococcal capsular polysaccharides by immunoelectrophoresis. J Clin Microbiol. 1982 Jun;15(6):1172–1175. doi: 10.1128/jcm.15.6.1172-1175.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Szu S. C., Stone A. L., Robbins J. D., Schneerson R., Robbins J. B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987 Nov 1;166(5):1510–1524. doi: 10.1084/jem.166.5.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Szu S., Lee C. J., Carlo D., Henrichsen J. Immunochemical characterization of cross-reactivity of pneumococcal group 9 capsular polysaccharide types 9N, 9A, 9L, and 9V. Infect Immun. 1981 Jan;31(1):371–379. doi: 10.1128/iai.31.1.371-379.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vann W. F., Soderstrom T., Egan W., Tsui F. P., Schneerson R., Orskov I., Orskov F. Serological, chemical, and structural analyses of the Escherichia coli cross-reactive capsular polysaccharides K13, K20, and K23. Infect Immun. 1983 Feb;39(2):623–629. doi: 10.1128/iai.39.2.623-629.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wessels M. R., Kasper D. L. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J Exp Med. 1989 Jun 1;169(6):2121–2131. doi: 10.1084/jem.169.6.2121. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES